Tazeen Ahmad
Stock Analyst at B of A Securities
(2.43)
# 2,274
Out of 4,826 analysts
198
Total ratings
42.28%
Success rate
-1.35%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $64.39 | +5.61% | 8 | Apr 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $273.55 | +18.81% | 3 | Mar 21, 2025 | |
| STRO Sutro Biopharma | Downgrades: Underperform | $11 → $1 | $1.05 | -4.76% | 2 | Mar 14, 2025 | |
| ARVN Arvinas | Maintains: Buy | $54 → $28 | $7.63 | +266.97% | 2 | Mar 12, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Neutral | $41 → $55 | $40.78 | +34.87% | 16 | Mar 11, 2025 | |
| MRUS Merus | Maintains: Buy | $73 → $70 | $43.34 | +61.51% | 5 | Mar 10, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $42 → $40 | $3.57 | +1,020.45% | 4 | Mar 10, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $30 → $28 | $15.95 | +75.55% | 2 | Mar 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $184 → $179 | $109.75 | +63.10% | 3 | Feb 7, 2025 | |
| PRTA Prothena Corporation | Maintains: Neutral | $26 → $22 | $8.08 | +172.28% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $13.10 | +68.00% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.44 | +108.33% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 → $47 | $19.98 | +135.24% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $62.11 | +44.90% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.55 | +129.18% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $7.17 | -16.32% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $170.74 | +11.87% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $101.10 | +48.37% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $5.69 | -64.85% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $656.65 | -7.56% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $63.66 | +234.59% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $38.87 | +95.52% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $15.18 | +44.93% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $1.49 | +842.76% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $1.82 | +450.96% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.17 | +412.82% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.72 | +94.43% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $18.66 | -41.05% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $11.03 | -9.34% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.42 | +40.85% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.82 | +627.36% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $10.25 | +46.34% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $39.04 | +53.71% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.19 | +1,250.21% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $8.61 | +399.42% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $161.27 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.25 | +3,143.24% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.61 | +1,375.41% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.72 | +86.63% | 6 | Oct 10, 2018 |
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $64.39
Upside: +5.61%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $273.55
Upside: +18.81%
Sutro Biopharma
Mar 14, 2025
Downgrades: Underperform
Price Target: $11 → $1
Current: $1.05
Upside: -4.76%
Arvinas
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.63
Upside: +266.97%
PTC Therapeutics
Mar 11, 2025
Upgrades: Neutral
Price Target: $41 → $55
Current: $40.78
Upside: +34.87%
Merus
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $43.34
Upside: +61.51%
4D Molecular Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $3.57
Upside: +1,020.45%
Denali Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $15.95
Upside: +75.55%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $109.75
Upside: +63.10%
Prothena Corporation
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $8.08
Upside: +172.28%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $13.10
Upside: +68.00%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.44
Upside: +108.33%
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $19.98
Upside: +135.24%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $62.11
Upside: +44.90%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.55
Upside: +129.18%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $7.17
Upside: -16.32%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $170.74
Upside: +11.87%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $101.10
Upside: +48.37%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $5.69
Upside: -64.85%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $656.65
Upside: -7.56%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $63.66
Upside: +234.59%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $38.87
Upside: +95.52%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $15.18
Upside: +44.93%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $1.49
Upside: +842.76%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $1.82
Upside: +450.96%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.17
Upside: +412.82%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $7.72
Upside: +94.43%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $18.66
Upside: -41.05%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $11.03
Upside: -9.34%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.42
Upside: +40.85%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.82
Upside: +627.36%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $10.25
Upside: +46.34%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $39.04
Upside: +53.71%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.19
Upside: +1,250.21%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $8.61
Upside: +399.42%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $161.27
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.25
Upside: +3,143.24%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.61
Upside: +1,375.41%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.72
Upside: +86.63%